This inventor holds 1 USPTO granted patent and 7 published patent applications. Top assignee: Link Medicine Corporation. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: The Innovations of Craig J Justman
Introduction
Craig J Justman is a notable inventor based in Cambridge, MA, who has made significant contributions to the field of neurodegenerative diseases. His work focuses on developing novel compounds that can potentially treat various neurological disorders. With one patent to his name, Justman is recognized for his innovative approach to addressing complex medical challenges.
Latest Patents
Justman's most recent patent is titled "Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications." This patent introduces new quinolinone farnesyl transferase inhibitors that are useful in the treatment or prevention of synucleinopathies, including Parkinson's Disease, Diffuse Lewy Body Disease, and multiple system atrophy. Additionally, these compounds are beneficial for disorders related to brain iron concentration and other neurodegenerative diseases. The provided compounds also show promise in treating proliferative diseases such as cancer, as well as neurological conditions like cognitive impairment, depression, and anxiety. The treatment involves administering a therapeutically effective amount of the inventive farnesyl transferase inhibitor compound to a subject.
Career Highlights
Craig J Justman is associated with Link Medicine Corporation, where he continues to advance his research and development efforts. His work at the company reflects his commitment to finding innovative solutions for complex health issues.
Collaborations
Justman has collaborated with notable colleagues, including Peter T Lansbury and Ross A Fredenburg, who share his passion for advancing medical science and improving patient outcomes.
Conclusion
Craig J Justman is a dedicated inventor whose work in developing quinolinone farnesyl transferase inhibitors holds great potential for treating various neurological and proliferative diseases. His contributions to the field are significant and reflect a commitment to innovation in medical research.